Evidence map›Paper›PMID 40472027›Full record

ArticleEpigenetics2025

Transcriptional signature of cardiac myocyte recovery in mice and human reveals persistent upregulation of epigenetic factors.

Rebekka Roth, Margareta Häckh, Tilman Schnick, Carolin Rommel, Christoph Koentges, Heiko Bugger, Claudia Domisch, Michael R Bristow, Amrut V Ambardekar, Timothy A McKinsey and 3 more

Abstract read
In one paragraph

Article in Epigenetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Rebekka RothInstitute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Freiburg, Germany.
Margareta HäckhInstitute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Freiburg, Germany.
Tilman SchnickInstitute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Freiburg, Germany.
Carolin RommelInstitute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Freiburg, Germany.
Christoph KoentgesDepartment of Cardiology and Angiology, Faculty of Medicine, University Heart Center, University of Freiburg, Germany.
Heiko BuggerDepartment of Cardiology and Angiology, Faculty of Medicine, University Heart Center, University of Freiburg, Germany.
Claudia DomischInstitute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Freiburg, Germany.
Michael R BristowDepartment of Medicine, Division of Cardiology and Consortium for Fibrosis Research & Translation, University of Colorado Anschutz Medical Campus, Denver, CO, USA.
Amrut V AmbardekarDepartment of Medicine, Division of Cardiology and Consortium for Fibrosis Research & Translation, University of Colorado Anschutz Medical Campus, Denver, CO, USA.
Timothy A McKinseyDepartment of Medicine, Division of Cardiology and Consortium for Fibrosis Research & Translation, University of Colorado Anschutz Medical Campus, Denver, CO, USA.
Ralf GilsbachInstitute of Experimental Cardiology, Heidelberg University Hospital, Heidelberg, Germany.
Lutz HeinInstitute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Freiburg, Germany.
Sebastian PreisslInstitute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Freiburg, Germany.

Funding

Colorado Clinical and Translational Sciences Institute (CCTSI)UM1TR004399 · NCATS · UNIVERSITY OF COLORADO DENVER · PI JANINE A HIGGINS, RONALD J. SOKOL · 2023 to 2026
$30.7M
15-PGDH-Mediated Eicosanoid Degradation in Cardiac Fibrosis and Heart FailureR01HL171711 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI Timothy McKinsey · 2024 to 2026
$1.6M
NCATS NIH HHS UM1 TR004399NHLBI NIH HHS R01 HL171711
6 · The paper itself

Abstract

Fibrosis, cardiac remodelling, and inflammation are hallmarks of heart failure. To date, there is no available pharmacological cure for heart failure, but mechanical unloading by implantation of a left ventricular assist device (LVAD) can lead to improved cardiac function in a subset of patients. This study aimed to identify the transcriptional response of left ventricular (LV) cardiac myocytes to mechanical unloading in a mouse model of reversible LV pressure overload and in failing human hearts after LVAD implantation. We found that partial recovery of ventricular dysfunction, LV hypertrophy, and gene expression programmes occurred in mice under reversible transverse aortic constriction (rTAC). Gene expression analysis in cardiac myocytes identified a lasting repression of mitochondrial gene expression resulting in compromised fatty acid oxidation in the mouse model of reversible pressure overload and in human LV samples after LVAD therapy and a persistent upregulation of epigenetic and transcriptional regulators. These findings underpin that recovery from heart failure involves complex gene regulatory networks and that mitochondrial dysfunction remains a challenge even after mechanical unloading. Further studies are needed to investigate the functional role of these factors in reverse remodelling and recovery of failing hearts.

Indexed as

Epigenesis, GeneticHeart FailureMyocytes, CardiacAnimalsHeart-Assist DevicesHumansMaleMiceTranscriptomeUp-RegulationVentricular RemodelingepigeneticsHeart failuremechanical unloadingmitochondriareverse remodelingtranscriptome

Identifiers

PMID40472027
PMCPMC12143706

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.